# Morgan Stanley

May 18, 2006

Stock Rating
Overweight
Industry View
Attractive

#### Tata Tea

### Cost Pressures; But Long-Term Story Intact

Cost pressures as tea cost rise: We were on a conference call with the management of Tata Tea to discuss their outlook on tea prices and potential impact on the company's businesses. We conclude that, although there some medium-term tea cost pressures, particularly for Tetley, the structural story in Tata Tea – i.e. potential gain in global market share in branded teas and restructuring of its plantations businesses – remains intact.

#### Tea prices expected to soften from the current

levels: Considering that tea is an agri commodity, predicting its price is often fraught with risk. However, Tata Tea management expects tea prices in India to soften from the current levels with fresh increase in supply over the next 2-4 weeks. Domestic prices are expected to end the year around 5% higher than last year, however. Kenyan tea prices have risen sharply by 29% YTD (Source: Indian Tea Association) on drought concerns and crop shortfall. Although drought concerns have mitigated, crop shortfall remains high, at around 40mn kgs. Kenyan tea prices are expected to soften from current levels, with fresh supply of crop as rainfall has improved. Kenyan tea prices are, however, expected to be around 10-15% higher during C2006 yoy.

Price hikes to mitigate cost pressures: Tata Tea has already taken a price hike of around 1-2% (weighted average) in its domestic business, in line with competition, to offset its cost pressures. Management is not averse to taking further price hikes in case cost pressures escalate. In its international business, the company typically manages with a couple of months of tea stocks. According to last published annual report, total raw material stock for the consolidated business is around 110 days. Tetley has not yet taken a price hike for its consumers, as it is mitigating its cost pressures partly by using cheaper blends of tea. But, if the auction tea prices in Kenya remain high, it is likely to take price hikes.

#### MORGAN STANLEY RESEARCH ASIA/PACIFIC

JM Morgan Stanley Securities
Private Limited+

#### Hozefa Topiwalla

Hozefa.Topiwalla@morganstanley.com +91 22 2209 7808

#### Padmanabhan Balasubramaniam

Padmanabhan.B@morganstanley.com +91 22 2209 7730

#### **Key Ratios and Statistics**

#### Reuters: TTTE.BO Bloomberg: NTT IN

#### **India Consumer**

Price target	Rs975.00
Shr price, close (May 17, 2006)	Rs830.05
Mkt cap, curr (mn)	Rs46,665
52-Week Range	Rs1,047.00-523.75

Fiscal Year (Mar)	2005	2006e	2007e	2008e
ModelWare EPS (Rs)*	45.61	51.94	58.47	64.75
Rev, net (Rs mn)	30,413	30,309	31,869	33,577
ModelWare net inc (Rs mn)	2,564	2,920	3,287	3,640
P/E	11.5	16.0	14.2	12.8
P/BV	2.0	2.7	2.4	2.1
EV/EBITDA	8.3	9.8	8.7	7.6
Div yld (%)	1.9	1.3	1.4	1.6

<sup>\* =</sup> Please see explanation of Morgan Stanley ModelWare later in this note.

Morgan Stanley does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section.

+= Analysts employed by non-U.S. affiliates are not registered pursuant to NASD/NYSE rules.

e = Morgan Stanley Research estimates

### Morgan Stanley JM MORGAN STANLEY

May 18, 2006 Tata Tea

Plantation restructuring on track: Tata Tea management continues to pursue restructuring of its North Indian plantations. It is likely that some developments will materialize in F2007. In our view, restructuring (hive-off) of their plantation business should free management resources for further strengthening of the branded tea business globally and reduce the overall volatility in earnings of its domestic business. The market is likely to view this development positively, in our opinion.


Inorganic growth likely to continue: Tata Tea has made two acquisitions in the recent past, firstly Goodearth in the US and secondly Jemca in the Czech Republic. However, both these together contribute less than 5% of the company's consolidated revenues. The company continues to pursue its global acquisition strategy to gain market share and consolidate the highly fragmented global tea industry. The company will continue to seek global opportunities both large and small. In our view, it is likely that the company will make some more progress in F2007.

#### Q3F2006 margin pressures in Tetley exceptional:

Management reiterated that the 35% decline in Tetley's PBT in Q3F2006 was largely exceptional marketing investments which are unlikely to recur. Tetley has been awarded best beverages brand in the UK in C2005. Also the Good Earth acquisition is performing ahead of expectations.

Currency impact in Q4: On our estimates, Tata Tea's consolidated numbers are likely to be impacted negatively in Q4 due to 5.5% YoY appreciation of the Indian Rupee vis-àvis the GBP. Also, its tea sourcing costs will be positively impacted during the same period as the USD has depreciated by 5.3% vis-à-vis the GBP. However, both of the abovementioned currency trends appear to have reversed in the first six weeks of F2007.

Exhibit 1
INR to GBP Depreciating since April



Source: Bloomberg, Morgan Stanley Research

Exhibit 2
CTC Tea Leaf Auction Prices: Spot



Source: Calcutta Tea Traders Association, Morgan Stanley Research

Exhibit 3 **Tea Prices Comparison** 

	Jan-l	Jan-March		
Centre	2006	2005	YoY	
Kolkata	63.7	59.9	6.3%	
Guwahati	58.0	54.7	6.1%	
Cochin	53.6	54.7	-1.9%	
Chittagong	63.5	78.8	-19.4%	
Jakarta	115.9	103.3	12.1%	
Mombasa	202.0	157.0	28.7%	
Limbe	115.0	89.8	28.0%	
Colombo	197.4	193.5	2.0%	

Source: Indian Tea Association, Morgan Stanley Research

#### **Company Description**

Tata Tea is the largest integrated tea company in the world. After its recent acquisition of the Tetley Group, Tata Tea is second only to Unilever in the branded tea market. The company enjoys a 19% value share of the Indian packaged tea market. It also has a presence in the coffee business through its subsidiary, Tata Coffee.

#### **Industry View: Attractive**

We believe the industry is on a recovery path driven by a pickup in rural and urban demand and an improving pricing environment

#### **MSCI Country: India**

Asia Strategist's Recommended Weight: 1.8% MSCI Asia/Pac All Country Ex Jp Weight: 6.3%

May 18, 2006 Tata Tea

Morgan Stanley

MødelWare<sup>SM</sup>

ModelWare is Morgan Stanley's new system for helping investors and analysts to uncover value, free from the distortions and ambiguities created by accounting data. Morgan Stanley has dissected and fundamentally redefined the components of corporate valuation, giving clients more consistent definitions, more comparable data, and more flexible analytic tools. ModelWare makes investment insights easier by making value more visible.

Past inconsistencies in financial reporting made it difficult to compare performance among companies and across sectors and regions. Even within US GAAP, flexibility complicates comparisons. And accounting standards were developed to analyze historical data, not to facilitate projections. In response, Morgan Stanley analysts spent two years reviewing our entire coverage universe of company metrics. They defined more than 2,000 general and industry-specific metrics that eliminated inconsistencies stemming from regional differences, historical precedents and accounting conventions. The team applied these metrics across also all 1900+ companies we cover, and created flexible tools and services that let analysts redefine and use the data with maximum creativity. Because ModelWare provides complete transparency, users see every component of every calculation, to choose elements or recombine them as they wish.

**ModelWare EPS illustrates the approach.** It represents ModelWare EPS as ModelWare net income divided by average fully diluted shares outstanding. ModelWare net income sums net operating profit after tax (NOPAT), net financial income or expense (NFE) and other income or expense. ModelWare adjusts reported net income to improve comparability across companies, sectors and regions. Among these adjustments: We exclude goodwill amortization and items deemed by analysts to be "one-time" events; we capitalize operating leases where their use is significant (e.g., in transportation and retail); and we convert inventory to FIFO accounting when LIFO costing is used. For more information on these adjustments and others, as well as additional background, please see *Morgan Stanley ModelWare (ver. 1.0): A Road Map for Investors*, by Trevor Harris and team, August 2, 2004.

••

May 18, 2006 Tata Tea

#### **Disclosure Section**

The information and opinions in this report were prepared or are disseminated by Morgan Stanley Dean Witter Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Dean Witter Asia (Singapore) Pte. (Registration number 199206298Z, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley & Co. International Limited, Taipei Branch and/or Morgan Stanley & Co International Limited, Seoul Branch, and/or Morgan Stanley Dean Witter Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or JM Morgan Stanley Securities Private Limited and their affiliates (collectively, "Morgan Stanley").

#### **Analyst Certification**

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Hozefa Topiwalla.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

#### **Global Research Conflict Management Policy**

This research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

#### Important US Regulatory Disclosures on Subject Companies

The following analyst, strategist, or research associate (or a household member) owns securities in a company that he or she covers or recommends in this report: Hozefa Topiwalla - ITC Ltd. (common stock), Hindustan Lever (common stock). Morgan Stanley policy prohibits research analysts, strategists and research associates from investing in securities in their sub industry as defined by the Global Industry Classification Standard ("GICS," which was developed by and is the exclusive property of MSCI and S&P). Analysts may nevertheless own such securities to the extent acquired under a prior policy or in a merger, fund distribution or other involuntary acquisition.

As of April 28, 2006, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in this report: Colgate-Palmolive India, Hindustan Lever, ITC Ltd., Marico Limited.

As of April 28, 2006, Morgan Stanley held a net long or short position of US\$1 million or more of the debt securities of the following issuers covered in this report (including where guarantor of the securities): Colgate-Palmolive India, Hindustan Lever, Nestle India.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Colgate-Palmolive India, ITC Ltd..

Within the last 12 months, Morgan Stanley & Co. Incorporated has received compensation for products and services other than investment banking services from Colgate-Palmolive India, Marico Limited, Nestle India.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following companies covered in this report: Colgate-Palmolive India, ITC Ltd..

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following companies covered in this report: Colgate-Palmolive India, Marico Limited, Nestle India.

Within the last 12 months, Morgan Stanley has either provided or is providing non-securities related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following companies covered in this report: Marico Limited.

The research analysts, strategists, or research associates principally responsible for the preparation of this research report have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

#### STOCK RATINGS

Different securities firms use a variety of rating terms as well as different rating systems to describe their recommendations. For example, Morgan Stanley uses a relative rating system including terms such as Overweight, Equal-weight or Underweight (see definitions below). A rating system using terms such as buy, hold and sell is not equivalent to our rating system. Investors should carefully read the definitions of all ratings used in each research report. In addition, since the research report contains more complete information concerning the analyst's views, investors should carefully read the entire research report and not infer its contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

#### **Global Stock Ratings Distribution**

(as of April 30, 2006)

#### MORGAN STANLEY RESEARCH

### Morgan Stanley JM MORGAN STANLEY

May 18, 2006 Tata Tea

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Underweight to hold and sell recommendations, respectively.

	Coverage	Universe	Investment	Banking Clie	ents (IBC)
_				% of Total 9	% of Rating
Stock Rating Category	Count	% of Total	Count	IBC	Category
Overweight/Buy	713	36%	261	41%	37%
Equal-weight/Hold	883	45%	295	46%	33%
Underweight/Sell	367	19%	84	13%	23%
Total	1,963		640		

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley or an affiliate received investment banking compensation in the last 12 months.

#### **Analyst Stock Ratings**

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

More volatile (V) - We estimate that this stock has more than a 25% chance of a price move (up or down) of more than 25% in a month, based on a quantitative assessment of historical data, or in the analyst's view, it is likely to become materially more volatile over the next 1-12 months compared with the past three years. Stocks with less than one year of trading history are automatically rated as more volatile (unless otherwise noted). We note that securities that we do not currently consider "more volatile" can still perform in that manner.

Unless otherwise specified, the time frame for price targets included in this report is 12 to 18 months.

#### **Analyst Industry Views**

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Stock price charts and rating histories for companies discussed in this report are available at www.morganstanley.com/companycharts or from your local investment representative. You may also request this information by writing to Morgan Stanley at 1585 Broadway, (Attention: Equity Research Management), New York, NY, 10036 USA.

#### Other Important Disclosures

For a discussion, if applicable, of the valuation methods used to determine the price targets included in this summary and the risks related to achieving these targets, please refer to the latest relevant published research on these stocks. Research is available through your sales representative or on Client Link at www.morganstanley.com and other electronic systems.

This report does not provide individually tailored investment advice. It has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The securities discussed in this report may not be suitable for all investors. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in this report may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

This report is not an offer to buy or sell or the solicitation of an offer to buy or sell any security or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section lists all companies mentioned in this report where Morgan Stanley owns 1% or more of a class of common

#### MORGAN STANLEY RESEARCH

Morgan Stanley

JM MORGAN STANLEY

May 18, 2006 Tata Tea

securities of the companies. For all other companies mentioned in this report, Morgan Stanley may have an investment of less than 1% in securities or derivatives of securities of companies mentioned in this report, and may trade them in ways different from those discussed in this report. Employees of Morgan Stanley not involved in the preparation of this report may have investments in securities or derivatives of securities of companies mentioned in this report, and may trade them in ways different from those discussed in this report. Derivatives may be issued by Morgan Stanley or associated persons.

Morgan Stanley & Co. Incorporated and its affiliate companies do business that relates to companies covered in its research reports, including market making and specialized trading, risk arbitrage and other proprietary trading, fund management, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in its research reports on a principal basis.

With the exception of information regarding Morgan Stanley, reports prepared by Morgan Stanley research personnel are based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in this report change apart from when we intend to discontinue research coverage of a subject company. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley research personnel conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits.

The value of and income from your investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in your securities transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. Unless otherwise stated, the cover page provides the closing price on the primary exchange for the subject company's securities.

To our readers in Taiwan: Information on securities that trade in Taiwan is distributed by Morgan Stanley & Co. International Limited, Taipei Branch (the "Branch"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. This publication may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities. The Branch may not execute transactions for clients in these securities.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Dean Witter Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning this publication, please contact our Hong Kong sales representatives.

Certain information in this report was sourced by employees of the Shanghai Representative Office of Morgan Stanley Dean Witter Asia Limited for the use of Morgan Stanley Dean Witter Asia Limited.

This publication is disseminated in Japan by Morgan Stanley Japan Securities Co., Ltd.; in Hong Kong by Morgan Stanley Dean Witter Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Dean Witter Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore, which accepts responsibility for its contents; in Australia by Morgan Stanley Dean Witter Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services licence No. 233742, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International Limited, Seoul Branch; in India by JM Morgan Stanley Securities Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of this publication in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that this document has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated and Morgan Stanley DW Inc., which accept responsibility for its contents. Morgan Stanley & Co. International Limited, authorized and regulated by Financial Services Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International Limited representative about the investments concerned. In Australia, this report, and any access to it, i

The trademarks and service marks contained herein are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities is available on request.

#### MORGAN STANLEY RESEARCH

## Morgan Stanley JM MORGAN STANLEY

The Americas 1585 Broadway New York, NY 10036-8293 United States Tel: +1 (1) 212 761 4000

Europe
25 Cabot Square, Canary Wharf
London E14 4QA
United Kingdom
Tel: +44 (0) 20 7 425 8000

Japan 4-20-3 Ebisu, Shibuya-ku Tokyo 150-6008 Japan Tel: +81 (0) 3 5424 5000 Asia/Pacific
Three Exchange Square
Central
Hong Kong
Tel: +852 2848 5200

#### **Industry Coverage:India Consumer**

Company (Ticker)	Rating (as of) Pri	ice (05/17/2006)
Hozefa Topiwalla		
Colgate-Palmolive India	O (01/10/2005)	Rs413.30
(COLG.BO)		
Hindustan Lever (HLL.BO)	O (08/01/2005)	Rs275.35
ITC Ltd. (ITC.BO)	O (03/12/2004)	Rs204.85
Marico Limited (MRCO.BO)	O (03/07/2006)	Rs521.65
Nestle India (NEST.BO)	O (05/02/2002)	Rs1181.85
Tata Tea (TTTE.BO)	Overweight	Rs830.05
, ,	(04/08/2004)	

Stock Ratings are subject to change. Please see latest research for each company.